Senores Pharmaceuticals Ltd
SENORESSenores Pharmaceuticals Ltd's earnings have outrun its stock. EPS grew +96.9% in a year against a +96.2% price move.
The sharpest disagreement: profits are rising, but only −5% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (54 weeks in) while the P/E sits at the 67th percentile of its own 2-year range. Underneath, the last four quarters read improving — profit +42.9% year on year, and −5% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Senores Pharmaceuticals Ltd trades at ₹1,306, in a confirmed uptrend and 54 weeks into that stage. That is +33.0% against its own 200-day average. It sits at 85% of a 52-week range of ₹674 to ₹1,418. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 23 straight weeks.
Today the stock is in a confirmed uptrend — week 54 of stage 2, confirmed. At ₹1,306 it trades +33.0% versus its 200-day average and sits at 85% of its 52-week range (₹674–₹1,418).
Against the market, two honest reads. Cumulative: over the last 1.6 years the stock moved +128% while the NIFTY 500 moved +6% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 23 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Senores Pharmaceuticals Ltd trades at 47.6× P/E, mid-range by its own standards (67th percentile). Its long-run median P/E is 43.8×, measured across 1.6 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 47.6× is mid-range by its own standards (67th percentile), against a long-run median of 43.8× measured over 1.6 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +96.9% against a +96.2% price move — earnings outran the price, pushing the multiple DOWN its own range.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 13% on reported income across 10 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Senores Pharmaceuticals Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 7 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +59.0% | +162.5% | — | — |
| Profit | +110.3% | +148.0% | — | — |
| EPS | +96.9% | +42.9% | — | — |
| Share price | +96.2% | — | — | — |
4-Factor Sector Score
73.8/100 — rank 1 of 14 in Pharma - API · 75% evidence confidence
Senores Pharmaceuticals Ltd scores 73.8 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 1. Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
The four contributions add to the total exactly: 32.4 + 16.4 + 9.4 + 15.6 = 73.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Senores Pharmaceuticals Ltd reported ₹180 Cr of revenue in the Jun 26 quarter, +30.4% year on year. That is the 7th straight quarter of year-on-year growth. Over 4 years it has compounded at 159.3% a year. The last full year, FY26, came in at ₹633 Cr. The last four reported quarters add to ₹688 Cr.
FY26 revenue came in at ₹633 Cr (+59.0% on the year), capping 4 years at 159.3% compound. The latest quarter (Jun 26) printed ₹180 Cr, +30.4% year on year — the 7th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +52.6% growth against the decade's 159.3% — the current year is running slower than its own long-run rate.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Senores Pharmaceuticals Ltd's operating margin is 30.0% in the Jun 26 quarter, +5.0 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 14.0% to 36.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 30.0%, +5.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 14.0%–36.0%.
Why the margin moved: operating margin went +5.1 pp year on year while gross margin went +8.0 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Senores Pharmaceuticals Ltd earned ₹30.0 Cr of net profit in the Jun 26 quarter, +42.9% year on year. It is the 7th consecutive quarter of growth. Full-year FY26 profit was ₹122 Cr. The 4-year compound rate is 232.3%. That is 16.7% of the quarter's revenue. The same quarter a year earlier earned ₹21.0 Cr.
Jun 26 profit was ₹30.0 Cr, +42.9% year on year — the 7th consecutive quarter of growth. On the full year, FY26 printed ₹122 Cr (+110.3%), and the 4-year compound rate is 232.3%.
Why profit moved: revenue contributed +30.4% and the margin +5.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +97.9% vs revenue +52.6%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years −5% of Senores Pharmaceuticals Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹62.0 Cr of operating cash against ₹122 Cr of profit. After ₹330 Cr of capital spending, ₹−268 Cr was left as free cash.
FY26: operating cash of ₹62.0 Cr against reported profit of ₹122 Cr, leaving free cash of ₹−268 Cr after ₹330 Cr of capital spending. Across the last 3 fiscal years the conversion rate is −5% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at −5%: the cash cycle tightened 341 days between FY22 and FY26 — cash that used to wait in the cycle now reaches the bank sooner. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: the bigger cash user is investment — capital spending ran 13.3× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Senores Pharmaceuticals Ltd's cash conversion cycle runs −24 days in FY26, down from 317 days in FY22. Capital spending ran ₹769 Cr over the last 3 years. At FY26 sales of ₹633 Cr each day of that cycle holds about ₹1.7 Cr, so roughly ₹−42.0 Cr sits inside the business at any moment.
FY26: debtors at 187 days, inventory at 130 days — roughly 4.3 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −24 days, tighter than FY22's 317.
The full loop: cash goes out to suppliers and production on day 0; stock waits 130 days to sell; customers pay about 187 days after that; and suppliers themselves are paid at 340 days — netting out to the −24-day cycle.
In money terms: at FY26 sales of ₹633 Cr, each day of the cycle holds about ₹1.7 Cr — so the −24-day loop keeps roughly ₹−42.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹769 Cr over the last 3 fiscal years against ₹58.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹17.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Senores Pharmaceuticals Ltd earns a ROCE of 15% in FY26. That is up from a trough of 11% in FY25. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 19.3% net margin on 0.39× asset turns.
FY26 ROCE is 15%, recovered from a FY25 trough of 11% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 19.3% net margin × 0.39× asset turns × 1.72× balance-sheet leverage ≈ 12.9% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 13% on reported income across 10 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Senores Pharmaceuticals Ltd carries ₹342 Cr of borrowings against ₹934 Cr of equity in FY26, a debt-to-equity of 0.37. Operating profit covers the interest bill 7×. Over 4 years borrowings went from ₹15.0 Cr to ₹342 Cr. Capital spending ran ₹769 Cr across the last 3 of those years.
FY26: borrowings of ₹342 Cr against equity of ₹934 Cr — a debt-to-equity of 0.37. Operating profit covers the interest bill 7×. Over 4 years borrowings went from ₹15.0 Cr to ₹342 Cr while capital spending ran ₹769 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 13% on reported income across 10 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions added 2.4 points of Senores Pharmaceuticals Ltd over 6 quarters, the biggest move on the register. That takes foreign institutions to 6.6% of the company. Domestic institutions moved −2.0 points over the same window, to 9.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +2.4 points over 6 quarters to 6.6%; Domestic institutions: −2.0 points over 6 quarters to 9.8%; Promoters: +0.0 points over 6 quarters to 45.8%.
Why the register moved: rotation — foreign institutions +2.4 points against domestic institutions −2.0 points over 6 quarters, with promoters holding steady — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Senores Pharmaceuticals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Senores Pharmaceuticals Ltdthis pageSENORES | 73.8/100Favorable setup75% evidence | LEADER | 32.4/35 Revenue 50.9% · PAT 92.7% · OPM change 5 pp 95% evidence | 16.4/25 ROCE 15.1% · OPM 30% 76% evidence | 9.4/20 P/E 47.6× · PEG — 15% evidence | 15.6/20 RS sector 19.5% · RS bench 44.3% · 1Y 95.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 32.4 + 16.4 + 9.4 + 15.6 = 73.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Wanbury LtdWANBURY | 71.2/100Favorable setup73% evidence | TURNING | 25.7/35 Revenue 16.5% · PAT 45.5% · OPM change 6 pp 71% evidence | 19.5/25 ROCE 36.6% · OPM 16% 95% evidence | 12.1/20 P/E 23.9× · PEG — 50% evidence | 13.9/20 RS sector 5.3% · RS bench 12.9% · 1Y 20.1%7 of 11 weeks ahead 70% evidence |
| Exact sum: 25.7 + 19.5 + 12.1 + 13.9 = 71.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Innova Captab LtdINNOVACAP | 65.1/100Favorable setup96% evidence | LEADER | 22.2/35 Revenue 31.1% · PAT 10.2% · OPM change 0 pp 88% evidence | 15.6/25 ROCE 15% · OPM 15% 100% evidence | 13.8/20 P/E 39.7× · PEG 1.01 100% evidence | 13.5/20 RS sector -1.4% · RS bench 19.9% · 1Y 7.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 15.6 + 13.8 + 13.5 = 65.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Jagsonpal Pharmaceuticals LtdJAGSNPHARM | 56.9/100Mixed-positive evidence81% evidence | TURNING | 15.7/35 Revenue 3.2% · PAT -24.6% · OPM change 2 pp 95% evidence | 18.2/25 ROCE 22.7% · OPM 21% 95% evidence | 11.2/20 P/E 32.4× · PEG — 50% evidence | 11.8/20 RS sector 0.7% · RS bench 9.7% · 1Y -12.3%10 of 10 weeks ahead 70% evidence |
| Exact sum: 15.7 + 18.2 + 11.2 + 11.8 = 56.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Fermenta Biotech LtdFERMENTA | 56.3/100Mixed-positive evidence70% evidence | TURNING | 11.4/35 Revenue 11.9% · PAT -6.6% · OPM change -10 pp 83% evidence | 18.0/25 ROCE 20.6% · OPM 16% 95% evidence | 11.0/20 P/E 23.4× · PEG — 15% evidence | 15.9/20 RS sector 15.7% · RS bench 49.3% · 1Y 33.5%3 of 7 weeks ahead 70% evidence |
| Exact sum: 11.4 + 18 + 11 + 15.9 = 56.3 · Decision use: Price leads the evidence: RS versus the benchmark is 49.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 6Ind-Swift Laboratories LtdINDSWFTLAB | 55.3/100Mixed-positive evidence83% evidence | BREAKING OUT | 22.3/35 Revenue 100% · PAT -80% · OPM change 19 pp 83% evidence | 6.5/25 ROCE 4.7% · OPM 12% 95% evidence | 6.5/20 P/E 39.4× · PEG — 50% evidence | 20.0/20 RS sector 39.4% · RS bench 68% · 1Y 114.3%9 of 12 weeks ahead 100% evidence |
| Exact sum: 22.3 + 6.5 + 6.5 + 20 = 55.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Aarti Drugs LtdAARTIDRUGS | 49.3/100Mixed-negative evidence94% evidence | TURNING | 18.2/35 Revenue 10.5% · PAT 1.1% · OPM change 1 pp 100% evidence | 10.6/25 ROCE 11.9% · OPM 14% 100% evidence | 13.3/20 P/E 20× · PEG 2.4 100% evidence | 7.2/20 RS sector -10.7% · RS bench 0.7% · 1Y -21.4%4 of 10 weeks ahead 70% evidence |
| Exact sum: 18.2 + 10.6 + 13.3 + 7.2 = 49.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Anuh Pharma LtdANUHPHR | 47.8/100Mixed-negative evidence77% evidence | ASLEEP | 16.6/35 Revenue 16.5% · PAT -12.8% · OPM change 1 pp 83% evidence | 11.1/25 ROCE 14.9% · OPM 10% 95% evidence | 13.1/20 P/E 21.9× · PEG — 50% evidence | 7.0/20 RS sector -5.4% · RS bench -2.9% · 1Y -20%0 of 10 weeks ahead 70% evidence |
| Exact sum: 16.6 + 11.1 + 13.1 + 7 = 47.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Beta Drugs LtdBETA | 45.6/100Mixed-negative evidence76% evidence | TURNING | 11.7/35 Revenue -11.3% · PAT -14.8% · OPM change 2 pp 95% evidence | 18.6/25 ROCE 19.2% · OPM 22% 76% evidence | 7.1/20 P/E 51× · PEG — 50% evidence | 8.2/20 RS sector -17.9% · RS bench 35.1% · 1Y 30.5%9 of 10 weeks ahead 70% evidence |
| Exact sum: 11.7 + 18.6 + 7.1 + 8.2 = 45.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Kopran LtdKOPRAN | 42.1/100Mixed-negative evidence77% evidence | TURNING | 16.6/35 Revenue 8.3% · PAT -34.2% · OPM change 4 pp 83% evidence | 9.6/25 ROCE 6.7% · OPM 14% 95% evidence | 8.1/20 P/E 35.8× · PEG — 50% evidence | 7.8/20 RS sector -17.6% · RS bench 19.4% · 1Y 10.6%11 of 11 weeks ahead 70% evidence |
| Exact sum: 16.6 + 9.6 + 8.1 + 7.8 = 42.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Gujarat Themis Biosyn LtdGUJTHEM | 39.8/100Mixed-negative evidence89% evidence | ASLEEP | 14.8/35 Revenue 8.6% · PAT -6.1% · OPM change 2 pp 88% evidence | 18.3/25 ROCE 17.9% · OPM 44% 100% evidence | 6.4/20 P/E 83.6× · PEG 2.77 65% evidence | 0.3/20 RS sector -22.1% · RS bench -4.7% · 1Y -1.2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 18.3 + 6.4 + 0.3 = 39.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 12Themis Medicare LtdTHEMISMED | 28.7/100Adverse evidence68% evidence | BREAKING OUT | 13.0/35 Revenue -15.6% · PAT -80% · OPM change 15.7 pp 62% evidence | 2.4/25 ROCE 2.7% · OPM 4.9% 95% evidence | 8.5/20 P/E 587× · PEG — 15% evidence | 4.8/20 RS sector -17.2% · RS bench 0.9% · 1Y -10%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 2.4 + 8.5 + 4.8 = 28.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Aarti Pharmalabs LtdAARTIPHARM | 27.4/100Adverse evidence90% evidence | ASLEEP | 7.3/35 Revenue -14% · PAT -31.3% · OPM change -7 pp 88% evidence | 11.3/25 ROCE 10.7% · OPM 19% 100% evidence | 3.3/20 P/E 34.2× · PEG 5.52 100% evidence | 5.5/20 RS sector -10.7% · RS bench -11.7% · 1Y -29.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 7.3 + 11.3 + 3.3 + 5.5 = 27.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Orchid Pharma LtdORCHPHARMA | 19.0/100Adverse evidence90% evidence | TURNING | 5.9/35 Revenue -11.8% · PAT -79.8% · OPM change -1 pp 88% evidence | 2.9/25 ROCE 2.6% · OPM 11% 100% evidence | 2.7/20 P/E 184× · PEG 4.09 100% evidence | 7.5/20 RS sector -19.8% · RS bench 29.8% · 1Y 38.9%11 of 11 weeks ahead 70% evidence |
| Exact sum: 5.9 + 2.9 + 2.7 + 7.5 = 19 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Senores Pharmaceuticals Ltd's share price today?
Senores Pharmaceuticals Ltd trades at ₹1,306, +96.2% over the past year. The company is valued at ₹6,013 Cr. The stock sits at 85% of its 52-week range of ₹674–₹1,418, +33.0% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 54 weeks in. — as of 31 July 2026.
What were Senores Pharmaceuticals Ltd's latest quarterly results?
Senores Pharmaceuticals Ltd reported revenue of ₹180 Cr and net profit of ₹30.0 Cr for the Jun 26 quarter. Revenue rose 30.4% and profit rose 42.9% year on year. Earnings per share were ₹6.67. The operating margin was 30.0%, 5.0 pp higher than a year earlier. — as of 31 July 2026.
What is Senores Pharmaceuticals Ltd's revenue?
Senores Pharmaceuticals Ltd reported revenue of ₹180 Cr in the Jun 26 quarter, +30.4% year on year. For the full FY26 fiscal year, revenue was ₹633 Cr (+59.0%). Over the last 4 years revenue compounded at 159.3% a year. — as of 31 July 2026.
What is Senores Pharmaceuticals Ltd's profit?
Senores Pharmaceuticals Ltd earned ₹30.0 Cr of net profit in the Jun 26 quarter, +42.9% year on year — the 7th straight quarter of growth. Full-year FY26 profit was ₹122 Cr. The operating margin ran 30.0% in the latest quarter. — as of 31 July 2026.
What is Senores Pharmaceuticals Ltd's market cap?
Senores Pharmaceuticals Ltd's market capitalisation is ₹6,013 Cr at a share price of ₹1,306. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Senores Pharmaceuticals Ltd's P/E ratio?
Senores Pharmaceuticals Ltd trades at a P/E of 47.6×, at the 67th percentile of its own 2-year range, against a long-run median of 43.8×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Senores Pharmaceuticals Ltd pay a dividend?
No — Senores Pharmaceuticals Ltd has recorded a dividend payout of 0% of profit in each of its last 5 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 31 July 2026.
Is Senores Pharmaceuticals Ltd overvalued?
On its own history, Senores Pharmaceuticals Ltd looks expensive against its own history: its P/E of 47.6× sits at the 67th percentile of its 2-year range (long-run median 43.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Senores Pharmaceuticals Ltd growing?
Yes — Senores Pharmaceuticals Ltd is growing: latest-quarter revenue +30.4% year on year, profit +42.9%, and the margin +5.0 pp at 30.0%. The 4-year compound rates are 159.3% (revenue) and 232.3% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Senores Pharmaceuticals Ltd performing?
Senores Pharmaceuticals Ltd is in a confirmed uptrend, 54 weeks in. Its latest quarter's revenue rose 30.4% and profit rose 42.9% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 23 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
Is Senores Pharmaceuticals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 54 of stage 2), trading +33.0% versus its 200-day average and at 85% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Senores Pharmaceuticals Ltd beating the market?
On recent form, yes — Senores Pharmaceuticals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 23 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.6 years the stock moved +128% against the NIFTY 500's +6% — ahead of the index over the full window. — as of 31 July 2026.
Will Senores Pharmaceuticals Ltd's share price go up?
This page publishes no price forecast for Senores Pharmaceuticals Ltd. What it measures instead: the share price is ₹1,306, the price is in a confirmed uptrend 54 weeks in. Its P/E of 47.6× sits at the 67th percentile of its own 2-year range. — as of 31 July 2026.
Who owns Senores Pharmaceuticals Ltd?
Promoters hold 45.8% of Senores Pharmaceuticals Ltd, foreign institutions 6.6%, domestic institutions 9.8% and the public 37.8% (latest quarter). The biggest move on the register over the last two years: Foreign institutions added 2.4 points over 6 quarters. — as of 31 July 2026.
Does Senores Pharmaceuticals Ltd have too much debt?
It is moderate — Senores Pharmaceuticals Ltd's debt-to-equity is 0.37, and operating profit covers the interest bill 7×. FY26 borrowings were ₹342 Cr against equity of ₹934 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is Senores Pharmaceuticals Ltd's capex?
Senores Pharmaceuticals Ltd spent ₹769 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹330 Cr, with ₹17.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Senores Pharmaceuticals Ltd's cash flow?
Senores Pharmaceuticals Ltd generated ₹62.0 Cr of operating cash flow in FY26 and ₹−268 Cr of free cash flow after ₹330 Cr of capital spending. Reported profit that year was ₹122 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Senores Pharmaceuticals Ltd's profit real cash?
Not fully — over the last 3 fiscal years, −5% of Senores Pharmaceuticals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹62.0 Cr against reported profit of ₹122 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Senores Pharmaceuticals Ltd in its business cycle?
Senores Pharmaceuticals Ltd's FY26 operating margin was 27.0%, against a 5-year band of 14.0%–36.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 30.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Senores Pharmaceuticals Ltd story?
The sharpest disagreement: profits are rising, but only −5% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Senores Pharmaceuticals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Senores Pharmaceuticals Ltd's earnings have outrun its stock. EPS grew +96.9% in a year against a +96.2% price move. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.